{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:04:14Z","timestamp":1791576254494,"version":"4.3.4"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.2165\/11634300-000000000-00000","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T16:19:31Z","timestamp":1362500371000},"page":"71-100","source":"Crossref","is-referenced-by-count":53,"title":["Moxifloxacin Safety"],"prefix":"10.1007","volume":"12","author":[{"given":"Paul M.","family":"Tulkens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Arvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Kruesmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,12,18]]},"reference":[{"issue":"6","key":"12020071_CR1","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","volume":"17","author":"M. Woodhead","year":"2011","unstructured":"Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections: full version. Clin Microbiol Infect 2011; 17 Suppl. 6: E1\u201359.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"12020071_CR2","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","volume":"44","author":"L.A. Mandell","year":"2007","unstructured":"Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl. 2: S27\u201372.","journal-title":"Clin Infect Dis"},{"issue":"B","key":"12020071_CR3","doi-asserted-by":"crossref","first-page":"3B","DOI":"10.1155\/2003\/486285","volume":"10","author":"M.S. Balter","year":"2003","unstructured":"Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J 2003; 10 Suppl. B: 3B\u201332B.","journal-title":"Can Respir J"},{"issue":"2","key":"12020071_CR4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","volume":"50","author":"J.S. Solomkin","year":"2010","unstructured":"Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50 (2): 133\u201364.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"12020071_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.otohns.2003.12.001","volume":"130","author":"J.B. Anon","year":"2004","unstructured":"Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004; 130 (1 Suppl.): 1\u201345.","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"2","key":"12020071_CR6","first-page":"239","volume":"16","author":"Sociedad Espa\u00f1ola de Quimioterapia, Sociedad Espa\u00f1ola de Otorrinolaringolog\u00eda y Patolog\u00eda C\u00e9rvico-Facial","year":"2003","unstructured":"Sociedad Espa\u00f1ola de Quimioterapia, Sociedad Espa\u00f1ola de Otorrinolaringolog\u00eda y Patolog\u00eda C\u00e9rvico-Facial. Diagnosis and antimicrobial treatment of sinusitis. Rev Esp Quimioter 2003; 16 (2): 239\u201351.","journal-title":"Rev Esp Quimioter"},{"key":"12020071_CR7","unstructured":"Clinical Effectiveness Group, British Association for Sexual Health and HIV. UK national guideline for the management of pelvic inflammatory disease 2011 (updated June 2011) [online]. Available from URL: http:\/\/www.bashh.org\/documents\/3572 [Accessed 2012 Jan 28]."},{"issue":"10","key":"12020071_CR8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","volume":"41","author":"D.L. Stevens","year":"2005","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41 (10): 1373\u2013406.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"12020071_CR9","first-page":"13","volume":"52","author":"L.J. Eron","year":"2003","unstructured":"Eron LJ, Lipsky BA, Low DE, et al. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 Suppl. 1: 13\u201317.","journal-title":"J Antimicrob Chemother"},{"key":"12020071_CR10","unstructured":"Pham PA, Bartlett JG. Moxifloxacin [online]. Available from http:\/\/www.hopkinsguides.com\/hopkins\/ub\/view\/Johns_Hopkins_ABX_Guide\/540355\/all\/Moxifloxacin [Accessed 2012 Jan 28]."},{"issue":"3","key":"12020071_CR11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00003495-199957030-00007","volume":"57","author":"J.A. Balfour","year":"1999","unstructured":"Balfour JA, Wiseman LR. Moxifloxacin. Drugs 1999; 57 (3): 363\u201373.","journal-title":"Drugs"},{"issue":"1","key":"12020071_CR12","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/319377","volume":"32","author":"C. Krasemann","year":"2001","unstructured":"Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001; 32 Suppl. 1: S51\u201363.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"12020071_CR13","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ajhp\/58.5.379","volume":"58","author":"C.M. Culley","year":"2001","unstructured":"Culley CM, Lacy MK, Klutman N, et al. Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm 2001; 58 (5): 379\u201388.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"12020071_CR14","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1086\/319378","volume":"32","author":"D.A. Talan","year":"2001","unstructured":"Talan DA. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 32 Suppl. 1: S64\u201371.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"12020071_CR15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2165\/00003495-200262010-00002","volume":"62","author":"G.G. Zhanel","year":"2002","unstructured":"Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs 2002; 62 (1): 13\u201359.","journal-title":"Drugs"},{"issue":"1","key":"12020071_CR16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00128071-200203010-00004","volume":"3","author":"J.M. Blondeau","year":"2002","unstructured":"Blondeau JM. The role of fluoroquinolones in skin and skin structure infections. Am J Clin Dermatol 2002; 3 (1): 37\u201346.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"12020071_CR17","doi-asserted-by":"crossref","first-page":"967","DOI":"10.2165\/00003495-200262060-00008","volume":"62","author":"R.B. Muijsers","year":"2002","unstructured":"Muijsers RB, Jarvis B. Moxifloxacin in uncomplicated skin and skin structure infections. Drugs 2002; 62 (6): 967\u201373.","journal-title":"Drugs"},{"issue":"7","key":"12020071_CR18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0149-2918(04)90170-1","volume":"26","author":"P. Ball","year":"2004","unstructured":"Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26 (7): 940\u201350.","journal-title":"Clin Ther"},{"issue":"20","key":"12020071_CR19","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.2165\/00003495-200464200-00006","volume":"64","author":"G.M. Keating","year":"2004","unstructured":"Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 2004; 64 (20): 2347\u201377.","journal-title":"Drugs"},{"issue":"10","key":"12020071_CR20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1368-5031.2004.00293.x","volume":"58","author":"C. Llor","year":"2004","unstructured":"Llor C, Naberan K, Cots JM, et al. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care. Int J Clin Pract 2004; 58 (10): 937\u201344.","journal-title":"Int J Clin Pract"},{"issue":"4","key":"12020071_CR21","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1469-0691.2005.01131.x","volume":"11","author":"F. Bambeke Van","year":"2005","unstructured":"Van Bambeke F, Michot JM, Van Eldere J, et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11 (4): 256\u201380.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"12020071_CR22","doi-asserted-by":"crossref","first-page":"S177","DOI":"10.1086\/428058","volume":"41","author":"S. Sethi","year":"2005","unstructured":"Sethi S. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Infect Dis 2005; 41 Suppl. 2: S177\u201385.","journal-title":"Clin Infect Dis"},{"issue":"7A","key":"12020071_CR23","doi-asserted-by":"crossref","first-page":"29S","DOI":"10.1016\/j.amjmed.2005.05.011","volume":"118","author":"R.F. Grossman","year":"2005","unstructured":"Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005; 118 Suppl. 7A: 29S\u201338S.","journal-title":"Am J Med"},{"issue":"3","key":"12020071_CR24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s15010-005-4102-8","volume":"33","author":"A.M. Ferrara","year":"2005","unstructured":"Ferrara AM. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 2005; 33 (3): 106\u201314.","journal-title":"Infection"},{"issue":"7","key":"12020071_CR25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1086\/512191","volume":"44","author":"C.L. Haggerty","year":"2007","unstructured":"Haggerty CL, Ness RB. Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clin Infect Dis 2007; 44 (7): 953\u201360.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"12020071_CR26","first-page":"191","volume":"2","author":"M. Miravitlles","year":"2007","unstructured":"Miravitlles M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD. Int J Chron Obstruct Pulmon Dis 2007; 2 (3): 191\u2013204.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"12020071_CR27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1517\/14656566.9.10.1755","volume":"9","author":"M. Miravitlles","year":"2008","unstructured":"Miravitlles M, Anzueto A. Moxifloxacin: a respiratory fluoroquinolone. Expert Opin Pharmacother 2008; 9 (10): 1755\u201372.","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"12020071_CR28","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1517\/14656566.9.10.1735","volume":"9","author":"S. Simoens","year":"2008","unstructured":"Simoens S, Decramer M. A pharmacoeconomic review of the management of respiratory tract infections with moxifloxacin. Expert Opin Pharmacother 2008; 9 (10): 1735\u201344.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"12020071_CR29","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1586\/eri.09.46","volume":"7","author":"O. Burkhardt","year":"2009","unstructured":"Burkhardt O, Welte T. 10 years\u2019 experience with the pneumococcal quinolone moxifloxacin. Expert Rev Anti Infect Ther 2009; 7 (6): 645\u201368.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"12020071_CR30","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1185\/03007990903223663","volume":"25","author":"S. Simoens","year":"2009","unstructured":"Simoens S. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines. Curr Med Res Opin 2009; 25 (10): 2447\u201357.","journal-title":"Curr Med Res Opin"},{"key":"12020071_CR31","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1016\/S1098-3597(03)90027-5","volume":"3","author":"K.A. Sprandel","year":"2003","unstructured":"Sprandel KA, Rodvold KA. Safety and tolerability of fluoroquinolones. Clin Cornerstone 2003; Suppl. 3: S29\u201336.","journal-title":"Clin Cornerstone"},{"issue":"B","key":"12020071_CR32","first-page":"34","volume":"16","author":"P.B. Iannini","year":"2004","unstructured":"Iannini PB. Fluoroquinolone toxicity: a review of class- and agent-specific adverse effects. Drug Benefit Trends 2004; 16 Suppl. B: 34\u201341.","journal-title":"Drug Benefit Trends"},{"issue":"5","key":"12020071_CR33","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00002018-200528050-00007","volume":"28","author":"V.T. Andriole","year":"2005","unstructured":"Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28 (5): 443\u201352.","journal-title":"Drug Saf"},{"key":"12020071_CR34","unstructured":"Choudri SH, Kuesmann K, Perroncel R. Cardiac safety of moxifloxacin in hospitalized patients with community-acquired pneumonia [abstract no. L-1079]. 46th Inter-science Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2006 Sep 27\u201330; San Francisco (CA)."},{"issue":"5","key":"12020071_CR35","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00002018-200932050-00001","volume":"32","author":"F. Bambeke Van","year":"2009","unstructured":"Van Bambeke F, Tulkens PM. Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32 (5): 359\u201378.","journal-title":"Drug Saf"},{"issue":"2","key":"12020071_CR36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14740338.1.2.121","volume":"1","author":"P.B. Iannini","year":"2002","unstructured":"Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin Drug Saf 2002; 1 (2): 121\u20138.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"12020071_CR37","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1185\/030079907X188099","volume":"23","author":"P.B. Iannini","year":"2007","unstructured":"Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations. Curr Med Res Opin 2007; 23 (6): 1403\u201313.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"12020071_CR38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2165\/00002512-200320040-00005","volume":"20","author":"R. Stahlmann","year":"2003","unstructured":"Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20 (4): 289\u2013302.","journal-title":"Drugs Aging"},{"issue":"3","key":"12020071_CR39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2165\/11531490-000000000-00000","volume":"27","author":"R. Stahlmann","year":"2010","unstructured":"Stahlmann R, Lode H. Safety considerations of fluoroquinolones in the elderly: an update. Drugs Aging 2010; 27 (3): 193\u2013209.","journal-title":"Drugs Aging"},{"issue":"S4","key":"12020071_CR40","first-page":"631A","volume":"40","author":"J.D. Grange","year":"2004","unstructured":"Grange JD, Thabut D, Lucidarme D, et al. Randomized, comparative study of moxifloxacin versus amoxicillin-clavulanate in the treatment of bacterial infections in cirrhotic patients [abstract no. 1086]. Hepatology 2004; 40 Suppl. S4:631A.","journal-title":"Hepatology"},{"key":"12020071_CR41","unstructured":"Avelox\u00ae: US prescribing information [online]. Available from URL: http:\/\/www.univgraph.com\/bayer\/inserts\/avelox.pdf [Accessed 2012 Jan 28]."},{"key":"12020071_CR42","unstructured":"Avelox\u00ae 400 mg\/250 mL solution pour perfusion: r\u00e9sum\u00e9 des caract\u00e9ristiques du produit [online]. Available from URL: http:\/\/www.fagg-afmps.be\/en\/ [Accessed 2012 Jan 28]."},{"key":"12020071_CR43","unstructured":"Avelox\u00ae 400 mg comprim\u00e9s: r\u00e9sum\u00e9 des caract\u00e9ristiques du produit [online]. Available from URL: http:\/\/www.faggafmps.be\/en\/ [Accessed 2012 Jan 28]."},{"issue":"2","key":"12020071_CR44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/147323000102900202","volume":"29","author":"H. Landen","year":"2001","unstructured":"Landen H, Moller M, Tillotson GS, et al. Clinical experience in Germany of treating community-acquired respiratory infections with the new 8-methoxyfluoroquinolone, moxifloxacin. J Int Med Res 2001; 29 (2): 51\u201360.","journal-title":"J Int Med Res"},{"issue":"1","key":"12020071_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00044011-200323010-00001","volume":"23","author":"J. Barth","year":"2003","unstructured":"Barth J, Landen H. Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis. Clin Dug Invest 2003; 23 (1): 1\u201310.","journal-title":"Clin Dug Invest"},{"issue":"5","key":"12020071_CR46","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1345\/aph.1C066","volume":"38","author":"G.A. Faich","year":"2004","unstructured":"Faich GA, Morganroth J, Whitehouse AB, et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004; 38 (5): 749\u201354.","journal-title":"Ann Pharmacother"},{"issue":"8","key":"12020071_CR47","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00044011-200424080-00001","volume":"24","author":"W. Elies","year":"2004","unstructured":"Elies W, Landen H, Stauch K. Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice: results of a post-marketing surveillance study. Clin Drug Investig 2004; 24 (8): 431\u20139.","journal-title":"Clin Drug Investig"},{"issue":"8","key":"12020071_CR48","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2165\/00044011-200424080-00003","volume":"24","author":"H. Koch","year":"2004","unstructured":"Koch H, Landen H, Stauch K. Daily-practice treatment of acute exacerbations of chronic bronchitis with moxifloxacin in a large cohort in Germany. Clin Drug Investig 2004; 24 (8): 449\u201355.","journal-title":"Clin Drug Investig"},{"issue":"8","key":"12020071_CR49","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00044011-200424080-00002","volume":"24","author":"H. Koch","year":"2004","unstructured":"Koch H, Landen H, Stauch K. Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice: evidence from a post-marketing surveillance study of 1467 patients. Clin Drug Investig 2004; 24 (8): 441\u20138.","journal-title":"Clin Drug Investig"},{"issue":"11","key":"12020071_CR50","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2165\/00044011-200525110-00002","volume":"25","author":"J. Barth","year":"2005","unstructured":"Barth J, Stauch K, Landen H. Efficacy and tolerability of sequential intravenous\/oral moxifloxacin therapy in pneumonia: results of the first post-marketing surveillance study with intravenous moxifloxacin in hospital practice. Clin Drug Investig 2005; 25 (11): 691\u2013700.","journal-title":"Clin Drug Investig"},{"issue":"12","key":"12020071_CR51","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00044011-200626120-00007","volume":"26","author":"T. Schaberg","year":"2006","unstructured":"Schaberg T, Moller M, File T, et al. Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice. Clin Drug Investig 2006; 26 (12): 733\u201344.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"12020071_CR52","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1742-1241.2007.01484.x","volume":"61","author":"L.Y. Liu","year":"2007","unstructured":"Liu LY, Landen H. Treatment of respiratory tract infections with moxifloxacin: results of postmarketing surveillance in China. Int J Clin Pract 2007; 61 (9): 1509\u201315.","journal-title":"Int J Clin Pract"},{"issue":"9","key":"12020071_CR53","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3109\/00016481003629036","volume":"130","author":"B. Zhou","year":"2010","unstructured":"Zhou B, Jiang X, Zhai L, et al. Moxifloxacin in the treatment of acute bacterial rhinosinusitis: results of a multicenter, non-interventional study. Acta Otolaryngol 2010; 130(9): 1058\u201364.","journal-title":"Acta Otolaryngol"},{"issue":"3","key":"12020071_CR54","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003495-199300453-00012","volume":"45","author":"S.R. Norrby","year":"1993","unstructured":"Norrby SR, Lietman PS. Safety and tolerability of fluoroquinolones. Drugs 1993; 45 Suppl. 3: 59\u201364.","journal-title":"Drugs"},{"issue":"6","key":"12020071_CR55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00002018-199513060-00004","volume":"13","author":"P. Ball","year":"1995","unstructured":"Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics: past, present and future. Drug Saf 1995; 13 (6): 343\u201358.","journal-title":"Drug Saf"},{"issue":"7","key":"12020071_CR56","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/S0149-2918(00)80053-3","volume":"22","author":"J. Bertino Jr","year":"2000","unstructured":"Bertino Jr J, Fish D. The safety profile of the fluoroquinolones. Clin Ther 2000; 22 (7): 798\u2013817.","journal-title":"Clin Ther"},{"issue":"1","key":"12020071_CR57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/dkg209","volume":"51","author":"P. Ball","year":"2003","unstructured":"Ball P. Adverse drug reactions: implications for the development of fluoroquinolones. J Antimicrob Chemother 2003; 51 Suppl. 1: 21\u20137.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"12020071_CR58","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1503\/cmaj.070652","volume":"177","author":"D.N. Juurlink","year":"2007","unstructured":"Juurlink DN, Park-Wyllie LY, Kapral MK. The effect of publication on internet-based solicitation of personal-injury litigants. CMAJ 2007; 177 (11): 1369\u201370.","journal-title":"CMAJ"},{"key":"12020071_CR59","unstructured":"European Medicines Agency. Withdrawal assessment report for garenoxacin mesylate (Garenoxacin): EMEA\/H\/C\/747 [online]. Available from http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/2010\/01\/WC500067888.pdf [Accessed 2011 Dec 13]."},{"key":"12020071_CR60","unstructured":"European Medicines Agency. Withdrawal assessment report for Factive. International nonproprietary name: gemifloxacin. Procedure no. EMEA\/H\/C\/995 [online]. Available from URL: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Application_withdrawal_assessment_report\/2010\/01\/WC500060988.pdf [Accessed 2011 Dec 13]."},{"key":"12020071_CR61","unstructured":"Bayer Schering Pharma-Bayer plc. Direct healthcare professional communication regarding moxifloxacin (Avelox\u00ae) and serious hepatic and bullous skin reactions [online]. Available from URL: http:\/\/www.mhra.gov.uk\/home\/groups\/pl-p\/documents\/websiteresources\/con014103.pdf [Accessed 2012 Jan 28]."},{"key":"12020071_CR62","unstructured":"European Medicines Agency. Moxifloxacin [online]. Available from URL: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Moxifloxacin\/human_referral_000114.jsp&mid=WC0b01ac0580024e9a [Accessed 2012 Jan 28]."},{"key":"12020071_CR63","unstructured":"Council for International Organizations of Medical Sciences Working Group. Introductory guide for Standardised MedDRA Queries (SMQs) Version 13.0. Chantilly (VA): MedDRA Maintenance and Support Services Organization, 2010."},{"key":"12020071_CR64","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline. Statistical principles for clinical trials: E9 [online]. Available from URL: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E9\/Step4\/E9_Guideline.pdf [Accessed 2012 Jan 28]."},{"issue":"1","key":"12020071_CR65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2307\/2530643","volume":"41","author":"S. Greenland","year":"1985","unstructured":"Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985; 41 (1): 55\u201368.","journal-title":"Biometrics"},{"issue":"2","key":"12020071_CR66","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/14656566.6.2.283","volume":"6","author":"M. Miravitlles","year":"2005","unstructured":"Miravitlles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005; 6 (2): 283\u201393.","journal-title":"Expert Opin Pharmacother"},{"issue":"3A","key":"12020071_CR67","first-page":"16S","volume":"117","author":"W.A. Craig","year":"2004","unstructured":"Craig WA. Overview of newer antimicrobial formulations for overcoming pneumococcal resistance. Am J Med 2004; 117 Suppl. 3A: 16S\u201322S.","journal-title":"Am J Med"},{"issue":"2","key":"12020071_CR68","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijantimicag.2004.10.007","volume":"25","author":"T.M. File","year":"2005","unstructured":"File TM, Garau J, Jacobs MR, et al. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin\/clavulanate (2000\/125mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains. Int J Antimicrob Agents 2005; 25 (2): 110\u20139.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"12020071_CR69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1517\/14656566.9.2.229","volume":"9","author":"J. Aspa","year":"2008","unstructured":"Aspa J, Rajas O, de Castro FR. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother 2008; 9 (2): 229\u201341.","journal-title":"Expert Opin Pharmacother"},{"issue":"24","key":"12020071_CR70","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.2165\/00003495-200363240-00008","volume":"63","author":"K.F. Croom","year":"2003","unstructured":"Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterial infections in the United States. Drugs 2003; 63 (24): 2769\u2013802.","journal-title":"Drugs"},{"key":"12020071_CR71","doi-asserted-by":"crossref","first-page":"3s","DOI":"10.1183\/09031936.02.00400402","volume":"36","author":"K.P. Klugman","year":"2002","unstructured":"Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J Suppl 2002; 36: 3s\u20138s.","journal-title":"Eur Respir J Suppl"},{"issue":"5","key":"12020071_CR72","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/jac\/dkl356","volume":"58","author":"I. Odenholt","year":"2006","unstructured":"Odenholt I, Cars O. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model. J Antimicrob Chemother 2006; 58 (5): 960\u20135.","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"12020071_CR73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3810\/pgm.2008.09.suppl52.284","volume":"120","author":"P.D. Lister","year":"2008","unstructured":"Lister PD. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae. Postgrad Med 2008; 120 (3 Suppl. 1): 46\u201352.","journal-title":"Postgrad Med"},{"key":"12020071_CR74","unstructured":"Brinker A. Telithromycin-associated hepatotoxicity [online]. Available from www.fda.gov\/ohrms\/dockets\/AC\/06\/slides\/2006-4266s1-01-07-FDA-Brinker.ppt [Accessed 2012 Jan 28]."}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2165\/11634300-000000000-00000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T09:42:01Z","timestamp":1562751721000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2165\/11634300-000000000-00000"}},"subtitle":["An Analysis of 14 Years of Clinical Data"],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["12020071"],"URL":"https:\/\/doi.org\/10.2165\/11634300-000000000-00000","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}